Jazz Pharmaceuticals(US:JAZZ) Prnewswire·2025-10-02 22:37Core Insights - The FDA has approved Zepzelca (lurbinectedin) in combination with atezolizumab as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy [1][6] - This combination therapy is now included in the National Comprehensive Cancer Network (NCCN) guidelines as a preferred regimen for ES-SCLC patients [1] - The Phase 3 IMforte trial demonstrated that the combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to atezolizumab alone [1] Company Developments - Jazz Pharmaceuticals is advancing the standard of care for ES-SCLC with the introduction of this new maintenance approach [1] - The company continues to pursue opportunities in cancer research aimed at improving patient outcomes [1][27] Clinical Trial Results - In the IMforte trial, the median overall survival for the Zepzelca and atezolizumab regimen was 13.2 months compared to 10.6 months for atezolizumab alone [1] - The median progression-free survival was 5.4 months for the combination therapy versus 2.1 months for atezolizumab alone [1] Adverse Reactions - Common adverse reactions for Zepzelca in combination with atezolizumab include decreased lymphocytes (55%), decreased platelets (54%), and decreased hemoglobin (51%) [2][21] - Serious adverse reactions occurred in 31% of patients, with fatal reactions reported in 5% of patients receiving the combination therapy [20] Market Context - Small cell lung cancer (SCLC) accounts for approximately 13% of lung cancers in the U.S., with around 30,000 new cases reported annually [3] - SCLC is known for its aggressive nature and rapid progression, highlighting the need for effective treatment options [3][4]